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Introduction: To determine the dose-limiting toxicity and recom-
mended dose (RD) of cisplatin (CDDP) combined with S-1 (tegafur,
5-chloro-2, 4-dihydroxypyridine, and potassium oxonate) for pa-
tients with non-small cell lung cancer and to evaluate efficacy and
toxicity of this regimen at RD.
Methods: Patients with stages III and IV non-small cell lung cancer
received 3-week cycles of treatment, each consisting of oral admin-
istration of S-1 at 80 mg/m2 in 2 divided doses per day for 14
consecutive days, intravenous administration of CDDP (60 mg/m2,
70 mg/m2, or 80 mg/m2) on the first day, and no medication during
the subsequent 7 days. The primary objective of phase I study was
to estimate the maximum tolerable dose and the RD, and the primary
end point of phase II study was response.
Results: RD of CDDP in the analysis of 18 eligible patients was 60
mg/m2. Evaluation of efficacy and toxicity at RD in 55 eligible
patients showed that partial response was observed in 18 patients
(32.7%, 95% confidence interval: 20.7–46.7%). The median sur-
vival time was 18.1 months, and the time to disease progression was
3.8 months. Grade 3 or severer adverse events were observed in 27
patients (49.1%).
Conclusions: CDDP combined with S-1 showed a satisfactory
overall survival time and acceptable toxicity profile. However, the
response as the primary end point did not reach the predetermined
threshold level.
Key Words: S-1, NSCLC (non-small cell lung cancer), Chemother-
apy, Phase I/II trial, Cisplatin.
(J Thorac Oncol. 2010;5: 702–706)
Lung cancer, with its high mortality rate, is the mostcommon cause of death from malignant tumors. Among
the various types of lung cancer, non-small cell lung cancer
(NSCLC) accounts for more than 80% of all patients with
lung cancer. Platinum-based two-drug combinations with
third-generation agents such as docetaxel,1 paclitaxel,2 gem-
citabine,3 and vinorelbine4 are standard first-line treatment for
metastatic NSCLC. Cisplatin (CDDP) plus pemetrexed or car-
boplatin, paclitaxel plus bevacizumab is an option for nonsqua-
mous NSCLC.5,6 Platinum-based chemotherapy has also been
applied to combined modality treatment with thoracic radiother-
apy or surgery in stage II, IIIA, or IIIB NSCLC.7–9 Although
chemotherapy plays an important role in the management of
patients with NSCLC, the benefits of chemotherapy are
modest and standard platinum-based regimens have signifi-
cant toxicities; thus, more effective and less toxic regimens
are needed. Although an important goal of such development
is to raise the survival rate, it is also crucial to minimize
adverse events, cost, and improve quality of life.
S-1 (Taiho Pharmaceutical Co., Ltd., Tokyo, Japan) is
an oral antineoplastic drug consisting of tegafur, which is a
prodrug of 5-fluorouracil (5-FU), and 2 modulators, 5-chloro-
2,4-dihydroxypyridine and potassium oxonate.10 Tegafur has
advantages of high bioavailability and small individual dif-
ferences in absorption. This substance is gradually converted
to 5-FU in liver. On the other hand, 5-chloro-2,4-dihydroxy-
pyridine antagonizes dihydropyrimidine dehydrogenase and
suppresses the metabolism of 5-FU in liver to help maintain
the blood level of 5-FU11 and prevents neurotoxicity by
suppressing the generation of metabolite F--alanine. Potas-
sium oxonate prevents gastrointestinal toxicity through inhi-
bition of orotate phosphoribosyl transferase and suppresses
the phosphorylation of 5-FU in the digestive tract.12–14
Ichinose et al.15 conducted a phase II study on the
combination of S-1 and CDDP chemotherapy in patients with
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advanced NSCLC, using the schedule defined by a phase I
study in patients with advanced gastric cancer (3-week ad-
ministration of S-1 with CDDP at 60 mg/m2 on day 8).
Because the approved dose of CDDP for NSCLC in Japan is
70 to 90 mg/m2 and many regimens use day 1 administration
of CDDP in a 3-week schedule, the Health, Labor and
Welfare Ministry of Japan requested to evaluate the day 1
administration of CDDP and S-1 in a 3-week schedule. For
this reason, we conducted the phase I/II study with 2-week
administration of S-1 combined with CDDP on day 1.
The purpose of the study is to define maximum toler-
ated dose (MTD) and recommended dose (RD) of CDDP in
the phase I study and evaluated response rate, survival, and
adverse events in the phase II study.
PATIENTS AND METHODS
Patient Eligibility
Patients satisfying the following criteria were eligible:
(1) clinical stage of IIIB (no indications of radical radiother-
apy) or IV with a diagnosis of NSCLC confirmed by histol-
ogy or cytology; (2) presence of a measurable lesion; (3) age
20 to 74 years at the time of enrollment; (4) Eastern Coop-
erative Oncology Group performance status of 0 to 1; and (5)
expected survival time of 3 months or more. Other eligibility
criteria included white blood cells (4 to 12  103/l), platelets
(100  103/l), hemoglobin (9.0 g/dl), total bilirubin
(1.5 times laboratory reference value), aspartate amino-
transferase and alanine aminotransferase (100 U/liter), al-
kaline phosphatase (2 times normal laboratory reference
value), creatinine clearance (60 ml/min), and oxygen partial
pressure (60 mmHg). Exclusion criteria included (1) pa-
tients with a history of severe drug sensitivity (not specified);
(2) patients taking other anticancer medication; (3) patients
with active infection; (4) patients with significant comorbid
medical conditions, including, but not limited to, heart fail-
ure, renal failure, hepatic failure, hemorrhagic peptic ulcer,
mechanical or paralytic ileus, or poorly controlled diabetes;
(5) patients with pleural effusion, ascites, or pericardial fluid
requiring drainage; (6) patients with symptomatic brain me-
tastasis; (7) patients with difficulty in controlling bowel
movements; (8) patients with prior malignancies within the
past 5 years of nontreatment or disease-free interval, with the
exception of carcinoma in situ; (9) pregnant, nursing, or
potentially pregnant women; and (10) patients considered
inappropriate by the principal or subinvestigator. The patients
meeting enrollment criteria were registered after obtaining
their written informed consent. This protocol was reviewed
and approved by institutional review boards at all participat-
ing institutes.
Treatment Schedule
CDDP was administered on the first day with 14 con-
secutive day administration of S-1 and no medication on the
subsequent 7 days (21 days in total). S-1 was prescribed at a
dose of 80 mg/d if body surface area was less than 1.25 m2,
100 mg/d if body surface area was 1.25–1.5 m2, or 120 mg/d
if body surface area was 1.5 m2 or more, divided into 2
doses/d. The dose of S-1 was reduced by one level (20 mg/d)
in patients with BSA 1.25 m2 if there were grade 4 leukocy-
topenia, neutropenia, or platelet counts below 10,000/mm3 or
grade 3 or more nonhematological toxicity including diarrhea,
stomatitis, or rash. If the dose reduction was required in patients
who received 80 mg/d (patients with BSA1.25 m2 or who had
dose reduction) it was reduced to a minimum of 50 mg/d.
Analysis for MTD and RD of CDDP (Phase I Trial)
RD Analysis
Doses of CDDP in the estimation of MTD were set in
increments of 10 mg/m2 starting from a dose of 70 mg/m2
(level 1). RD was defined as the dose that was one level lower
than MTD. If MTD was defined as more than 80 mg/m2
(level 2), no further dose increase was made, and RD was
set at 80 mg/m2.
MTD Analysis
MTD was estimated based on the analysis of dose-
limiting toxicity (DLT) as follows: (1) If DLT occurrence
was 0/3, CDDP dose was increased to 80 mg/m2; (2) If DLT
occurrence ranged from 1/3 to 2/3, 3 patients were added, and
70 mg/m2 of CDDP was repeated; (3) If DLT occurrence was
3/3, this level was judged as MTD; (4) If DLT occurrence
after adding 3 patients ranged from 1/6 to 2/6, CDDP dose
was increased to 80 mg/m2; and (5) If DLT occurrence was
3/6 or more, this level was judged as MTD. The same
procedures were repeated at the CDDP dose of 80 mg/m2,
except the dose was not increased further. If MTD was not
determined at 80 mg/m2, it was estimated to be more than 80
mg/m2. The level was evaluated at least 1 week after the
completion of protocol treatment.
Definition of DLT
DLT was defined by the following adverse events: (1)
persistence of grade 4 neutropenia for 4 days or more; (2)
neutropenic fever of 38°C or more; (3) grade 3 or 4 for
thrombocytopenia; (4) grade 3 or more severe nonhemato-
logic toxicity other than nausea, vomiting, anorexia, and
hyponatremia; and (5) any adverse event requiring reduction
of total S-1 dose below 75% of the planned dose per cycle.
Assessment of Response
Antitumor response was evaluated by computed to-
mography scan and magnetic resonance imaging at 4-week
intervals after the beginning of administration in comparison
with the baseline lesions taken within 2 weeks before enroll-
ment using “Response Evaluation Criteria in Solid Tumors
(RECIST) Guidelines.”
Safety Assessment
Adverse events were identified according to “National Can-
cer Institute Common Toxicity Criteria (NCI-CTC), Version 2.0.”
Sample Size Determination and Statistical
Analysis
Assuming the response would follow a binomial distri-
bution, enrollment of 54 patients was planned, so that an
expected response of 50% would be significant in a test at the
one-tailed significance level of /2  2.5% when the thresh-
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old response is 30% and the power of the test (1 ) is 80%.
The survival curve for eligible patients was estimated using
Kaplan-Meier method,16 and median survival time (MST),
1-year, and 2-year survival proportions were calculated.
RESULTS
Eligible Patients and Doses
From seven institutions in Japan, 18 patients were
enrolled in the phase I and 55 eligible patients in the phase II
study. The latter included six patients accrued in phase I at
RD. Table 1 shows characteristics of the total 67 patients.
Patients were enrolled between July 2004 and August 2005.
Recommended Dose
MTD and RD of CDDP were estimated with six pa-
tients in the 70 mg/m2 dose group (level 1) and six patients in
the 80 mg/m2 dose group (level 2), respectively. Severe
adverse events that should be regarded as DLT, such as
shock, disseminated intravascular coagulation, and bloody
stool, occurred in three patients (50.0%, three of six) during
second and later cycles in level 1. Thus, we considered that
level 1 corresponded to MTD and performed an additional
evaluation at the CDDP dose of 60 mg/m2 assigned as level
0 in six patients. In the 60 mg/m2 group (level 0), one patient
developed pneumonia during the second cycle, but no other
events corresponding to DLT were observed. Therefore, we
estimated that MTD of CDDP in this schedule was 70 mg/m2
and RD was level 0.
Compliance
We regarded as completion of a cycle if CDDP was
administered on the first day, and the patient took 28 doses of
S-1. The number of patients completing 1, 2, 3, and 4 or more
cycles was 50, 36, 34, and 25, respectively. The reasons of
noncompletion were adverse events in 11 patients, disease
progression in 6 patients, and refusal and inadvertent skip-
ping in 3 patients. In this trial, it was possible to administer
S-1 without dose reduction 90.9% of patients (50 of 55).
Response and Survival
Table 2 shows the antitumor response (RECIST) in the
55 patients in phase II part of the study, as determined by the
central review. Response was 32.7% (18 of 55), and 95%
confidence interval (CI) was 20.7 to 46.7%.
In the 18 responding patients, the median time to 30%
reduction in tumor size was 38 days (range, 19–60 days). The
reduction occurred during the first cycle in three patients
(16.7%), second cycle in seven patients (38.9%), and third
cycle in eight patients (44.4%). Median time to confirmation
of partial response was 75.5 days (range, 51–95 days). This
occurred during the third cycle in 10 patients (55.6%), fourth
cycle in 6 patients (33.3%), and fifth cycle in 2 patients
(11.1%). The median response duration was 104 days (range,
57–176 days).
At the time of analysis, there were 32 cases of progres-
sion and 38 death events. MST of the 55 patients was 18.1
months (95% CI: 13.3–23.2 months), 1-year survival propor-
tion was 65.2%, and 2-year survival proportion was 34%. The
median follow-up at the time of analysis was 31.0 months
(range, 29.3–33.0 months). The median time to disease pro-
gression was 3.8 months (95% CI: 3.1–5.7 months). Kaplan-
Meier curves are shown in Figures 1 and 2.
Adverse Events
Major adverse events observed in this trial were my-
elosuppression, gastrointestinal toxicity, abnormal liver, or
renal function (Table 3). No treatment-related deaths were
observed in this trial.
DISCUSSION
This study was conducted to determine the optimal
dose of CDDP on day1 in combination with 14-day admin-
TABLE 2. Response by Patient Characteristics
Characteristics
No. of
Patients
Response
Response
(%)CR PR SD PD NE
All 55 0 18 18 16 3 32.7a
Gender
Male 32 0 11 10 10 1 34.4
Female 23 0 7 8 6 2 30.4
Stage
IIIB 14 0 5 4 4 1 35.7
IV 41 0 13 14 12 2 31.7
Histology
Adenocarcinoma 43 0 14 12 14 3 32.6
Squamous cell
carcinoma
7 0 2 4 1 0 28.6
Others 5 0 2 2 1 0 40.0
CR, complete response; PR, partial response; SD, stable disease; PD, progressive
disease; NE, not evaluated.
a 95% confidence interval: 20.7–46.7%.
TABLE 1. Patient Characteristics
Phase I Phase II
CDDP (mg/m2) 70 80 60
No. of patients 6 6 55
Gender
Male 6 3 32
Female 0 3 23
Age, yr
Median 57 54 59
Range 49–69 37–66 36–74
ECOG performance status
0 2 2 20
1 4 4 35
Clinical stage
IIIB 3 1 14
IV 3 5 41
Histology
Adenocarcinoma 6 5 43
Squamous cell carcinoma 0 0 7
Others 0 1 5
CDDP, cisplatin; ECOG, Eastern Cooperative Oncology Group.
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istration of S-1 as 3-week cycle and to evaluate efficacy and
safety of the regimen at RD in patients with advanced
NSCLC. In phase I part of the study, MTD and RD of CDDP
were defined as 70 mg/m2 and 60 mg/m2, respectively. RD of
CDDP on day 1 was identical to day 8 administration of
CDDP used in the NSCLC phase II study by Ichinose et al.,15
which was based on RD of CDDP in combination chemo-
therapy for gastric cancer reported by Koizumi et al.17
The previous phase II study of 3-week administration
of S-1 combined with 60 mg/m2 of CDDP on day 8 showed
objective response of 47%, MST of 11.2 months, and 1-year
and 2-year survival proportions of 45% and 17%, respec-
tively. Although we must be careful to historically compare,
objective response was numerically higher in the previous
study with CDDP on given day 8 than this study with CDDP
on given day 1. Phase II part of this study demonstrated
that response in 55 patients was 32.7% (18 of 55, 95% CI:
20.7–46.7%) and did not reach the predetermined thresh-
old level.
Although objective response did not meet the threshold
level, the results of survival were encouraging with a MST of
18.1 months, a 1-year survival proportion of 65.2%, and a
2-year survival proportion of 34%. The relatively good sur-
vival results might in part be due to second-line treatment
with third-generation antineoplastic agents and/or molecular-
targeted agents: 74.5% of patients received second-line che-
motherapy including endothelial growth factor receptor ty-
rosine kinase inhibitors as poststudy treatment.
FIGURE 1. Overall survival.
FIGURE 2. Time to progression.
TABLE 3. Hematologic and Nonhematologic Toxicities (All
Cycles)a
Phase I
Phase II (Including 60 mg/m2
in Phase I)
CDDP (mg/m2) 70 80 60
No. of Patients 6 6 55
Toxicity
Grade Grade Grade
1 2 3 4 3 1 2 3 4 3 1 2 3 4 3
Leukopenia 1 1 2 1 3 1 1 2 — 2 16 11 3 — 3
Neutropenia 1 1 1 2 3 1 2 — 1 1 12 9 9 3 12
Anemia 3 1 1 1 2 3 — 2 — 2 20 18 5 2 7
Thrombocytopenia 3 1 1 — 1 1 — 1 — 1 21 7 3 — 3
Aspartate
aminotransferase
3 — — — — 3 — — — — 13 1 3 1 2
Alanine
aminotransferase
2 1 — — — 2 — — — — 17 2 1 1 2
Creatinine 2 1 — — — 1 — — — — 14 2 1 — 1
Anorexia 1 1 2 — 2 3 1 1 — 1 28 12 10 1 11
Vomiting 1 — — — — — 3 — — — 16 10 3 — 3
Diarrhea 3 — 1 — 1 3 — 1 — 1 19 5 4 — 4
Stomatitis 2 — 1 — 1 — 2 — — — 16 6 1 — 1
Pigmentation 2 1 — — — 3 — — — — 16 — — — —
Shock — — 1 — 1 — — — — — — — — — —
DIC — — 1 — 1 — — — — — — — — — —
Bloody stool — — — — — — — 1 — 1 — — — — —
a This table shows no. of patients.
DIC, disseminated intravascular coagulation.
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Preclinical studies showed the strongest antitumor ef-
fect was produced by the treatment with tegafur-uracil ad-
ministered both before and after CDDP.18 In addition, Satou-
chi et al. conducted a randomized phase II study of two
different schedules of S-1 and gemcitabine in patients with
advanced NSCLC. S-1 was administered daily from day 1 to
14, and gemcitabine was given on days 1 and 8 or days 8 and
15. Objective response, median time to progression, and MST
were favored for gemcitabine on days 8 and 15 schedule.19
Optimum sequence of S-1 in combination with other agents
has not been determined; however, S-1 and CDDP or gem-
citabine trials suggest that day 8 administration of other
agents is more effective than day 1 administration in combi-
nation with S-1.
In conclusion, the RD of CDDP on day 1 was identical
to that of day 8 administration of CDDP in combination with
S-1 in patients with advanced NSCLC. We have chosen day
8 administration schedule of CDDP and S-1 from days 1 to 21
as experimental arm in the phase III trial currently underway.
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